Drugs for the Treatment of Zika Virus Infection

Jean A. Bernatchez, Lana T. Tran, Jerry Li, Yepeng Luan, Jair L. Siqueira-Neto, Rongshi Li

Research output: Contribution to journalArticle

Abstract

Zika virus is an emerging flavivirus that causes the neurodevelopmental congenital Zika syndrome and that has been linked to the neuroinflammatory Guillain-Barré syndrome. The absence of a vaccine or a clinically approved drug to treat the disease combined with the likelihood that another outbreak will occur in the future defines an unmet medical need. Several promising drug candidate molecules have been reported via repurposing studies, high-throughput compound library screening, and de novo design in the short span of a few years. Intense research activity in this area has occurred in response to the World Health Organization declaration of a Public Health Emergency of International Concern on February 1, 2016. In this Perspective, the authors review the emergence of Zika virus, the biology of its replication, targets for therapeutic intervention, target product profile, and current drug development initiatives.

Original languageEnglish (US)
JournalJournal of Medicinal Chemistry
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Pharmaceutical Preparations
Flavivirus
Disease Outbreaks
Emergencies
Therapeutics
Vaccines
Public Health
Research
Zika Virus Infection
Zika Virus

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Bernatchez, J. A., Tran, L. T., Li, J., Luan, Y., Siqueira-Neto, J. L., & Li, R. (Accepted/In press). Drugs for the Treatment of Zika Virus Infection. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.9b00775

Drugs for the Treatment of Zika Virus Infection. / Bernatchez, Jean A.; Tran, Lana T.; Li, Jerry; Luan, Yepeng; Siqueira-Neto, Jair L.; Li, Rongshi.

In: Journal of Medicinal Chemistry, 01.01.2019.

Research output: Contribution to journalArticle

Bernatchez, Jean A. ; Tran, Lana T. ; Li, Jerry ; Luan, Yepeng ; Siqueira-Neto, Jair L. ; Li, Rongshi. / Drugs for the Treatment of Zika Virus Infection. In: Journal of Medicinal Chemistry. 2019.
@article{3e91361147704f64abd05838cd538ebd,
title = "Drugs for the Treatment of Zika Virus Infection",
abstract = "Zika virus is an emerging flavivirus that causes the neurodevelopmental congenital Zika syndrome and that has been linked to the neuroinflammatory Guillain-Barr{\'e} syndrome. The absence of a vaccine or a clinically approved drug to treat the disease combined with the likelihood that another outbreak will occur in the future defines an unmet medical need. Several promising drug candidate molecules have been reported via repurposing studies, high-throughput compound library screening, and de novo design in the short span of a few years. Intense research activity in this area has occurred in response to the World Health Organization declaration of a Public Health Emergency of International Concern on February 1, 2016. In this Perspective, the authors review the emergence of Zika virus, the biology of its replication, targets for therapeutic intervention, target product profile, and current drug development initiatives.",
author = "Bernatchez, {Jean A.} and Tran, {Lana T.} and Jerry Li and Yepeng Luan and Siqueira-Neto, {Jair L.} and Rongshi Li",
year = "2019",
month = "1",
day = "1",
doi = "10.1021/acs.jmedchem.9b00775",
language = "English (US)",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",

}

TY - JOUR

T1 - Drugs for the Treatment of Zika Virus Infection

AU - Bernatchez, Jean A.

AU - Tran, Lana T.

AU - Li, Jerry

AU - Luan, Yepeng

AU - Siqueira-Neto, Jair L.

AU - Li, Rongshi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Zika virus is an emerging flavivirus that causes the neurodevelopmental congenital Zika syndrome and that has been linked to the neuroinflammatory Guillain-Barré syndrome. The absence of a vaccine or a clinically approved drug to treat the disease combined with the likelihood that another outbreak will occur in the future defines an unmet medical need. Several promising drug candidate molecules have been reported via repurposing studies, high-throughput compound library screening, and de novo design in the short span of a few years. Intense research activity in this area has occurred in response to the World Health Organization declaration of a Public Health Emergency of International Concern on February 1, 2016. In this Perspective, the authors review the emergence of Zika virus, the biology of its replication, targets for therapeutic intervention, target product profile, and current drug development initiatives.

AB - Zika virus is an emerging flavivirus that causes the neurodevelopmental congenital Zika syndrome and that has been linked to the neuroinflammatory Guillain-Barré syndrome. The absence of a vaccine or a clinically approved drug to treat the disease combined with the likelihood that another outbreak will occur in the future defines an unmet medical need. Several promising drug candidate molecules have been reported via repurposing studies, high-throughput compound library screening, and de novo design in the short span of a few years. Intense research activity in this area has occurred in response to the World Health Organization declaration of a Public Health Emergency of International Concern on February 1, 2016. In this Perspective, the authors review the emergence of Zika virus, the biology of its replication, targets for therapeutic intervention, target product profile, and current drug development initiatives.

UR - http://www.scopus.com/inward/record.url?scp=85073155596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073155596&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.9b00775

DO - 10.1021/acs.jmedchem.9b00775

M3 - Article

C2 - 31549836

AN - SCOPUS:85073155596

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

ER -